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ABSTRACT OF THESIS:

EXAMINING THE NEUROPROTECTIVE PROPERTIES OF 3DIMETHOXYBENZYLIDENE-ANABASINE (DMXB-A) IN A THIRD TRIMESTER
CHRONIC ETHANOL EXPOSURE MODEL IN RATS

Excitotoxicity caused by ethanol (ETOH) withdrawal (EWD) is highly
detrimental to the developing brain. Targeting this excitotoxicity has been shown to be a
promising approach for improving outcome following developmental ETOH exposure.
Activation of nicotinic acetylcholine receptors (nAChR), in the central nervous system
can be protective against EWD. We examined the ability of DMXB-A, a α7 nAChR
agonist, to reduce neurotoxicity caused by EWD in the hippocampus. To test this, an
organotypic hippocampal slice culture was used. Slices were exposed to ETOH (100mM)
or control medium. After 10 days, the slices were treated with DMXB-A (1, 3, or 10uM)
during EWD. After 24 hours of EWD cell damage in the CA1, CA3, and dentate gyrus of
the hippocampus was analyzed.

The combination of EWD and NMDA produced

increased toxicity compared to controls in the CA1 region, DMXB-A attenuated this
effect, suggesting that DMXB-A was protective against EWD neurotoxicity in vitro.
These findings are exciting because this drug is currently in clinical trials for a variety of
CNS conditions and so has significant translational potential. Further research is
necessary to better understand the extent of its neuroprotective properties and to
determine its ability to reduce behavioral deficits following prenatal ethanol exposure.
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Chapter 1:
Introduction
Ethanol Use, Abuse, and Outcomes
Background
Alcohol is one of the most commonly used drugs in the western world, with an
estimated 87% of individuals (18 years of age or older) reporting that they had consumed
alcohol at some point in their lifetime, 71% in the last year, and 56 % in the last month
(NIAAA, 2014). Though ethanol consumption alone is most often not problematic,
approximately 25% of the population (18 years or older) have reported binge drinking
(defined as 3 drinks for women and 4 drinks for men in two hours) in the last month and
about 7% reporting that they had engaged in heavy drinking (5 or more drinks in one
occasion on 5 days in a given month) (NIAAA, 2014).

These drinking patterns

sometimes lead to alcohol use disorders which can be problematic for the individual and
those around them. Ethanol consumption during pregnancy in women who have an
alcohol use disorder can have many negative effects on the newborn. The effects of
ethanol consumption during pregnancy on infant development have been reported for
many years. Some of the earliest examples of ethanol consumption during pregnancy can
be seen in ancient Greek and Roman beliefs, stating that being intoxicated at the time of
reproduction would lead to the birth of a “damaged child” (Calhoun & Warren, 2007).
Clinical descriptions of the association between maternal drinking and the development
of learning/attention disorders and physical deformations have been reported for several
decades. The first published report was in 1968 by a French physician and his colleagues
who described a set of characteristics in children who had been exposed to ethanol in
utero (Lemoine et al., 1968). In the United States, the syndrome was first identified by
Jones and Smith, who described a pattern of malformations in the offspring of mothers
who had consumed ethanol during pregnancy. This research led to the observation that
infants who were exposed to ethanol in utero could have a characteristic set of
abnormalities which has come to be called Fetal Alcohol Syndrome (FAS) (Jones &
Smith, 1973). In order to be diagnosed with the disorder the child has to have (a)
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evidence of a characteristic pattern of facial anomalies which can include short palpebral
fissures and abnormalities in the premaxillary zone (i.e. flat upper lip, flattened philtrum,
and flat midface), (b) evidence of pre- and/or postnatal growth retardation (born small
and fail to thrive i.e. low birth weight), and (c) evidence of CNS damage (microcephaly,
mental retardation, or neurobehavioral deficits) (Stratton, 1996). Because prenatal ethanol
effects vary in severity, with FAS being the most extreme case, a spectrum was
developed to aid in the description of children who were only marginally affected by
ethanol’s effects during gestation (Hoyme, et al. 2004). These guidelines that encompass
fetal ethanol effects without the full diagnosis of FAS are known as Fetal Alcohol
Spectrum Disorders (FASDs). These guidelines state that an infant exposed to ethanol
during pregnancy does not have to demonstrate all of the characteristic symptoms of FAS
to be considered to have an alcohol-related disorder (Jones, 2011). This aids families of
children affected by ethanol exposure by providing special services to those affected
(Jones, 2011). Due to better understanding of the disorder and its diagnosis, estimates of
the population affected by FAS/FASD have increased. Estimates taken in the United
States suggest that the prevalence of FAS is about 0.5-2.0 cases for every 1000 births
(National Institutes of Health., 2013). Recent studies have also shown that misdiagnoses
in children in foster/adoptive care is also very prevalent, where 80% of children who met
the criteria for diagnosis in the fetal alcohol spectrum had previously not been diagnosed
as having been exposed to prenatal alcohol (Chasnoff et al., 2015). Although exact
numbers on the prevalence of FASDs in the population are unknown, using conservative
estimates from 2012, there may be as many as three times as many cases of FASDs as
FAS (Centers for Disease Control, 2012). Healthcare and other indirect costs associated
with the disorder have put the likely annual cost of FASDs in the US as high as $3.6
billion (Olson, et. al., 2009). Drinking during pregnancy is the leading preventable cause
of mental retardation in modern civilization, and because this has remained an issue the
need for treatment is vital.
Outcomes of FASDs
Fetal Alcohol Spectrum Disorders are difficult to diagnose because the
morphological changes commonly found in more severe forms of FAS/FASDs may not
2

be present in all patients, sometimes leading to missed diagnoses or no diagnoses at all.
Treatment for these disorders is also difficult because no medication currently exists for
either FAS/FASDs. Because of this, physicians commonly use medication used to treat
behavioral disorders like attention deficit/hyperactivity disorders (ADD/ADHD).
Children living with FAS/FASDs typically have some behavioral/learning deficits along
with social/economic difficulties later in life (Bishop et al., 2007). Other characteristic
deficiencies in children with FAS and occasionally FASDs include prenatal and postnatal
growth problems (Mattson & Riley, 1998; Mattson et al., 1998 ; Riley et al., 2011).
Because there is now an accepted spectrum of severity with FASDs, ranging from minor
to severe, diagnoses of the disorder can be challenging. This is especially so in children
displaying minimal facial malformations, which is commonly associated with less
exposure to ethanol during gestation (Mattson et al., 2010). However, these less severe
cases do demonstrate deficits common to more severe FAS, including problems with
executive functioning, motor coordination, spatial learning, attention, and hyperactivity
(Jones, 2011; Mattson & Riley, 1998). Some cognitive and behavioral assessments have
been able to aid in diagnoses of children who had a history of ethanol exposure in utero,
as they showed impairments in working memory, planning, and cognitive flexibility
which are characteristic of FASD (Mattson et al., 2010). However, this is made difficult
because these cognitive deficits can oftentimes resemble characteristic symptoms of
ADHD. As many as 94% of children exposed to relatively large amounts of prenatal
alcohol could be diagnosed with attention deficit hyperactivity disorder (Peadon &
Elliott, 2010). Children with FAS/FASDs can also have impaired social functioning. This
problem can cause children with the disorder to experience negative life situations
including problems at home, school, and eventually in the workplace (Kully-Martens et
al., 2012). These issues associated with FASD present a multitude of problems for the
individual, their families and society.
Binge Drinking: Possible Mediator of FASD’s
Drinking alcohol during pregnancy is associated with many problems. After a
mother consumes alcohol it crosses the placental barrier and within minutes of the onset
of a drinking episode, the fetal alcohol content can equal that of the maternal blood
3

(Paintner, Williams, & Burd, 2012). Additionally, amniotic fluid retains a peak alcohol
concentration for a longer period of time due to the decreased ability of the fetus to either
metabolize or transfer the ethanol back to the mother, who can rapidly metabolize the
chemical, resulting in a prolonged exposure period (Nava-Ocampo et al., 2004).
Research on quantity, timing, and pattern of consumption of alcohol during pregnancy
and its effects on the fetus in animal models has been studied extensively to help create
models of fetal ethanol exposures effects (for review see Painter, 2012). However,
research suggests that certain patterns of consumption may be more harmful than others
and that exposure at different time points during development differentially affect certain
regions of the brain and other organ systems.
A characteristic pattern of consumption for many alcoholics is binge drinking
(defined above). In an animal model looking at prenatal development in the rat, binge
drinking led to greater elevations in blood alcohol content leading to higher peak periods
of ethanol exposure for the developing fetus (Livy et al., 2003). With binge drinking,
there is often a binge pattern of drinking followed by periods of withdrawal. This pattern
has been linked to more severe deficits in populations of children with FASDs (Paintner
et al., 2012). The amount of alcohol consumed may not be as important, in terms of
overall detrimental effects, as the pattern of drinking by the mother.
Alcohols Effects on the Developing Brain
The developing fetus is in a constant state of growth and change. Such changes
encompass the development of many structures including the brain and nervous system.
These systems are highly susceptible to the neurotoxic effects of ethanol during their
development (Rodier, 1994). Some of ethanol’s effects on the CNS include: disruption in
cellular metabolism, an increase in hypoxic events, the creation of free radicals, an
inhibition of DNA methylation, and membrane fluidization (For review see: AlfonsoLoeches & Guerri 2011; Berman & Hannigan 2000; Eckardt et al., 2006; Goodlett &
Horn, 2001 & 2005; Jones 2011, Olney, J. 2004; West et al., 1994). Each of these are
detrimental to the survival of a developing cellular network. One critical period of growth
is the third trimester of pregnancy; it is a time of rapid division and migration of neural
cells into their constituent networks. This period is often referred to as the brain growth
4

spurt (Dobbing & Sands 1979). Exposure to alcohol during this time can be especially
detrimental, affecting neuronal migration, synaptogenesis, myelination, dendritic
aborization, histone methylation and other aspects of brain maturation and differentiation
(For review see: Goodlett et al., 2005; Guo et al., 2011; Painter et al., 2012). Regions of
the brain that undergo extensive development during this time, e.g., cerebellum and
hippocampus, have been shown to be particularly sensitive to ethanol exposure during the
third trimester (Alfonso-Loeches & Guerri, 2011), demonstrating the importance of
timing.
Changes in the brain
Children with an FASD show characteristic disabilities that can be related back to
changes in the CNS. Through the advancement of neuroimaging techniques it has
become possible to study brains of children with an FASD. Using magnetic resonance
imaging (MRI) there are several distinct brain regions that are more typically affected by
ethanol exposure than others in both FAS and FASDs. Some structures affected have
shown decreases in white matter compared to typically developing peers. Archibald and
colleagues (2001) found in 12 children diagnosed with FAS that cerebellar gray and
white matter was significantly reduced when compared to patients without FAS
diagnoses. In children with FASDs there were differences in fiber tracts like the corpus
callosum compared to control participants (Fryer et al., 2009). Other regions affected by
prenatal ethanol exposure include the posterior cingulate, temporal lobe, and specific
areas of the frontal, occipital, and parietal lobes in both FAS and FASD (Riley & McGee,
2005; Mattson et al., 1994; Spottiswoode et al., 2011). Furthermore, moderate to heavy
exposure to ethanol has been shown to cause a decrease in myelination and thus cellular
signaling in both human studies and animal models (Fryer et al., 2009; Sowell et al.,
2008). Further understanding of the effects of ethanol exposure has led to more accurate
development of diagnostic tests related to behavior and cognition that have been used in
both human FASDs and animal models.
Of particular interest for this proposal are the effects of fetal ETOH (ethanol)
exposure on the hippocampus. Imaging studies using young children diagnosed with FAS
have not shown dramatic changes structurally to the hippocampus (Archibald et al., 2001;
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Riley & McGee, 2005), but because so many of the behavioral deficits associated with
FASDs are learning and memory oriented, it suggests that this structure may be partially
responsible for the deficits. Although the changes related to this structure may not be
apparent at the macro level it may be the case that cellular and molecular functioning in
this structure may be altered by ethanol exposure during development. The CA1 region of
the hippocampus appears to be especially sensitive to ethanol’s effects during late
prenatal and early postnatal development. Tran & Kelly (2003) reported there was cell
loss in the CA1 region of the hippocampus when ethanol was administered during the 3rd
trimester equivalent in rodents. Livy and colleagues (2003) found similar results when
ethanol was administered during the 3rd trimester equivalent in the CA1. However, they
also found a significant reduction in cell numbers and density in the CA3 region of the
hippocampus. Previous studies using in-vitro hippocampal cultures have shown that
ETOH exposure followed by withdrawal in the hippocampus drastically reduces survival
of the cells in several regions of the hippocampus (Barron et al., 2008; de Fibre, 2003 &
2005, Li et al., 2000 & 2002; Prendergast et al., 2000 & 2004; Wilkins et al., 2006). This
research has stimulated study into the cellular mechanisms related to ETOH exposure and
withdrawal in the hippocampus and how novel compounds may mitigate this damage.
Modeling FAS/FASDs in Animals
The use and development of animal models in studying FASDs is a critical
component and powerful tool in the process of understanding the disorder (for review
see, Patten et al., 2014). Some of the most important components to consider are the
species used, timing of alcohol administration (e.g. 1st, 2nd, or 3rd trimester), the level of
intoxication and the administration pattern. Rodents (mice, rats, guinea pigs) are the most
common species used in research accounting for over 50% of studies (Clancy et al.,
2007), and are the choice of animal for the current proposal. This proposal uses a rodent
model of ethanol exposure because of the similarities between human and rodent CNS
development (Dobbing & Sands 1979). Dose is also a very important consideration when
modeling ETOH exposure; the quantity used in an animal model is extremely important
in determining whether you are trying to model more or less severe ethanol effects. A
wide range of blood alcohol levels have been used ranging from 100-400mg/dl; this
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equates roughly to moderate to heavy binge-like ethanol exposure (Patten, 2014). The
route of administration is also important when considering an animal model because of
the various benefits and drawbacks. The most commonly used in modeling fetal ethanol
exposure includes voluntary drinking and intubation method (Patten, 2014). Both of these
methods can be used in adult pregnant female rats (modeling 1st and 2nd trimester) and
neonates (modeling 3rd trimester) (Patten, 2014). Intubation is more typically used for
controlled dosing, because voluntary consumption is highly subject to individual
differences. However, both higher and more moderate BACs resulting from these routes
of administration are correlated to increased neurotoxicity and decreased white matter in
a dose-dependent fashion (Patten, 2014).
The developing mammalian nervous system is particularly sensitive to the effects
of teratogenic compounds. During development, the burgeoning nervous system goes
through massive amounts of cell generation, migration and proliferation, and finally
pruning and cell death, processes which occur throughout life but at a slower pace (de
Graaf-Peters & Hadders-Algra, 2006; Patten et al., 2014). This process occurs at different
rates and times during gestation, with some regions going through rapid changes later in
development. Uniquely, small animals such as rodents go through this development at
different times than do humans. In humans, gestation occurs over three characteristic
trimesters (3, 3-month blocks) all of which occur prenatally. During these trimesters the
brain is going through rapid development, with the first two trimesters characterized by
the formation of the neural tube, gastrulation, some cell proliferation and migration. The
third trimester in humans is commonly referred to as the “brain growth spurt,” and is a
time where the brain is undergoing rapid growth (Dobbing & Sands 1979). In rodents,
gestation typically occurs within 18-23 days compared to around 280 days in humans.
Extensive research investigating the differences between human and animal CNS
development has produced maps known as “trimester equivalents” in rodents using
anatomical comparisons and differences in cellular number (both glial and neural) to
compare the development of the two species. The first trimester equivalent in rodents is
roughly during gestational days (GD) 1-10, with GD 10-20 roughly corresponding to the
2nd trimester, and the third trimester mostly occurring after birth during post natal days
(PND) 1-10 (Clancy et al., 2007). However, these times are not concrete and represent a
7

loosely organized trajectory that has considerable overlap throughout development.
Utilization of this information has informed researchers in producing models of diseases
and disorders that occur during these times. Investigating the effect of ethanol on the
developing fetus has produced several ethanol exposure methods that utilize either a
prenatal (exposure during gestation) or neonatal (exposure shortly after birth) paradigm
(Berman & Hannigan 2000). In the prenatal exposure paradigm, the pregnant dam is
exposed to ethanol either through diet or by intragastric intubation (Berman & Hannigan,
2000; Kelly & Streissguth 2000; Thomas et al., 2009). Prenatal exposure to ethanol has
been shown to lead to deficits in social behavior (e.g. play behavior, social recognition,
and

active

interaction),

activity

(hyperactivity

and

impulse

control),

and

learning/memory, which is associated with deficits found in FAS/FASDs in humans
(Berman & Hannigan 2000; Driscoll et al., 1990; Kelly & Steissguth, 2000). Other
behavioral characteristics associated with prenatal ethanol exposure include feeding
difficulties, low birth and brain weight, poor reflex development and motor function, and
increased activity. All of these have correlates with clinical populations of children with
FAS (Driscoll et al., 1990; Thomas et al., 2009).
Another model is used to focus more specifically on the effects of “3rd trimester”
exposure, in which rat pups are exposed to ethanol during the first weeks of postnatal life
(Goodlett & Johnson 1997; Goodlett & Peterson 1995; Kelly & Tran 1997; Riley et al.,
1993; Wellmann et al., 2010). With this model, the offspring receives ethanol either
through a temporary or indwelling intragastric feeding tube. For the model using oral
intubation the dose of ethanol typically ranges between 2 and 6 grams per kilogram
(g/kg) of ethanol a day, with higher doses (6 g/kg) producing BACs of more than 200
milligrams per deciliter (mg/dl) (Patten et al., 2014). An advantage of this model and
other intubation models is the relative ease with which the experimenter can control the
dose of ethanol received, resulting in fairly predictable BACs. Also, intragastric
intubations do not require surgical implantation of feeding tubes. Previous research has
shown that ETOH exposure using this method produces deficits in a variety of behavioral
paradigms that assess motor coordination (Idrus et al., 2011; Lewis et al., 2007; Thomas
et al., 2004), activity (Smith et al., 2012; Thomas et al., 2007), and learning and memory
(Hunt et al., 2009; Thomas et al., 2009; Tiwari et al., 2012). This evidence has helped
8

demonstrate the validity of the model because the deficits found closely parallel the
deficits commonly seen in clinical populations of FASDs (Kelly et al., 2000; Lewis et al.,
2007; Riley et al., 1993; Thomas et al., 2004; Tran et al., 2000; Wellman, 2010).
Summary:
The development of FAS/FASDs through the exposure to ethanol during prenatal
development remains an important social and clinical problem. There is no simple
solution for this disorder because of the various constraints discussed above and the
complicated nature of the disorder itself. As a result, research continues in the
development of better understanding some of the mechanisms that underlie the
development and consequences of FAS. This basic research is essential and may provide
potential relief for a disorder that currently has no clear solutions.
A Possible Treatment
Treating FAS
Currently, there are no effective clinically-approved pharmacotherapies for the
treatment of toxicity induced by ethanol withdrawal in the fetus or newborns that were
exposed to ethanol during pregnancy.

Therefore, it is clear that development of

pharmacotherapies aimed at reducing the damage caused by ETOH exposure are needed.
One type of pharmacotherapy for FAS/FASDs can either focus on reversal/prevention,
such that treatment is administered during gestation or shortly after birth when the
diagnosis of the disorder has not yet occurred (Riley et al., 2011). Classically, therapies
aimed at treating children with FAS/FASDs have been focused on providing supportive
and protective environments for optimal outcomes (Pruett et al., 2013). Medication for
the management of these cognitive symptoms are most often the same drugs used for the
management of disorders like ADHD, a comorbid diagnosis commonly made in children
with an FASD (Pruett et al., 2013). This treatment strategy has had mixed results in
children with FASDs where symptoms of inattention were not reduced (Doig et al.,
2007). Another study looking at a variety of treatments found that various medications whether they are stimulants, SSRIs, or mood stabilizers - have some degree of success in
patients with FAS, but no single medication could treat all the symptoms associated with
9

the disorder (Coe et al., 2001). Previous cellular and behavioral work in animals has
outlined the importance of ethanol withdrawal after exposure as being a potentially
treatable source of cellular toxicity related to FAS/FASDs. Neonates exposed to chronic
levels of ETOH often experience many periods of withdrawal during and after birth
because of binge-like exposure to ETOH during gestation. Withdrawal from ethanol in
the neonate is severely damaging to the CNS and produces many deficits demonstrated
both in cellular (de Fiebre et al., 2003; Li et al., 2004; Prendergast et al., 2000 & 2004)
and in-vivo models (Barron et al., 2008; Goodlett & Horn 2001; Thomas et al., 1997 a.
and b.). The development of a pharmacotherapy aimed at reducing the damage associated
with this ethanol withdrawal (EWD) is appealing because it is potentially a one-time
treatment that would protect the fetus or newborn after ethanol has left the system, either
during parturition or when a mother is seeking help for a use disorder. Most research has
focused on targets that are involved directly with the damaging effects of ethanol, and
because ethanol’s effects on the developing CNS are numerous, many compounds have
been studied for their potentially therapeutic effect. A few examples of compounds used
prenatally to treat the teratogenic effects of ethanol follow. Using in-vitro models,
researchers have examined ethanol’s ability to inhibit L1, an immunoglobulin responsible
for cell adhesion and neuronal migration. It is thought that if ethanol’s action on L1 could
be reversed pharmacologically that it would reduce ethanol’s damaging effects on the
fetus (Wilkemeyer et al., 2000). Other compounds like ascorbic acid (vitamin C) have
also been investigated in Xenopus embryos and was able reduce damage produced by
reactive oxygen species produced by chronic ethanol exposure (Peng et al., 2005). Other
compounds like buspirone and ipsapirone, both serotonergic agonists, have also been
used to prevent ethanol damage to serotonergic neurons during pregnancy (Pruett et al.,
2013). There is also much work focusing on reducing cell damage via the glutamatergic
system via direct action or modulation at the n-methyl-d-aspartate (NMDA) receptor. For
example, CP-101-606 (a novel NR2B NMDA receptor antagonist) and MK-801 (a
noncompetitive antagonist) were able to attenuate behavioral deficits caused by ethanol
exposure (Lewis et al., 2011; Thomas et al., 1997). Although much of the work using
various compounds that utilize different neuronal systems have had varying degrees of
success in reducing behavioral deficits and cellular damage related to ethanol exposure,
10

none of them have yet been approved for clinical treatment of this problem. Because of
this, research continues in searching for compounds that have potential in treating ethanol
withdrawal-related toxicity.
A Promising Candidate
The Cholinergic System
Because

no

clinically-approved

pharmacotherapy

currently

exists

to

treat/reduce/reverse the damage caused by ethanol/EWD, much research has been
conducted on various drugs that have been shown to have neuroprotective properties (as
described above). One promising avenue is using drugs that target cholinergic receptors,
which is the focus of this proposal.
The cholinergic system is one of the most widespread and commonly studied
systems in the nervous system. Its functions are varied by region, and span both the
central and peripheral nervous systems. In the CNS, the cholinergic system is thought to
be a facilitator of processes related to wakefulness and attention, and is thought to play a
critical role in both learning and memory (Thomas, 2003). Ethanol’s effects on the
cholinergic system are widespread, with exposure to high doses of ethanol during the 2nd
week of gestation producing a loss of immunoreactivity to choline-acetyltransferase
(ChAT, an enzyme that signals the presence of acetylcholine-containing cells) in the
medial septal nuclei, caudate, and putamen, but not a loss in the number of cells present
(Heaton et al., 1996; Nagahara & Handa 1999 a.). These results suggest that cholinergic
function was impaired in the first weeks of prenatal development, but research looking
further into development showed that eventually these deficits decreased and returned to
control levels (Nagahara & Handa 1999 a.). Also, physostigmine, an acetylcholinesterase
inhibitor that increases the amount of available ACh (acetylcholine), reduced
hyperactivity in rats following prenatal ETOH compared to controls (Nagahara & Handa
1999 b.). In addition, when exposed to ethanol during the last two weeks of gestation,
nicotine did not produce the typical alterations in locomotor behavior or an increase in
memory performance when compared to control animals (Nagahara & Handa 1999 b.).
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Ethanol is also thought to affect both cholinergic receptor systems (muscarinic
and nicotinic) within the developing CNS. For the muscarinic system, studies have found
that during postnatal development there is an up-regulation of muscarinic ACh receptors
in the hippocampal formation in response to ethanol exposure (Nio et al., 1991). Also in
these same studies, scopolamine (a muscarinic antagonist) impaired fetal ETOH-exposed
rats in an alternation based task. Finally, when exposed to ethanol during early postnatal
development, PND 4 and 8 (via intragastric intubation), rats showed an increase in
striatal muscarinic receptor affinity (Light et al., 1989). Sex differences were again
observed; ETOH-exposed female rats had fewer cholinergic receptors in the striatum and
cerebellum (Light et al., 1989). This evidence suggests that exposure to ethanol during
development alters the function of the muscarinic cholinergic system and may affect
males and females differently.
The Nicotinic Receptor System
The nicotinic receptor system is a component of the cholinergic system and plays
many crucial roles in both the peripheral and central nervous systems. The receptor is
named so because of its high affinity for nicotine (a psychoactive chemical commonly
found in tobacco). These receptors were the first membrane receptor proteins identified in
the 1970s (Dani, 2001). They fall into a class of ligand-gated ion channels that respond
endogenously to acetylcholine or exogenously to nicotine (Dani, 2001; Pauly et al.,
2004). The function and location of the receptor in either the CNS or peripheral nervous
system (PNS) is dependent upon the type and arrangement of its subunits. The nicotinic
receptor is an ion-channel that is made of five membrane-spanning regions; each of the
five constituent regions is composed of different or similar subunits (Wu & Lukas, 2011).
The subunits that form nicotinic receptors in neural tissue include alpha (2-9) and beta (24); these subunits can be arranged in many different conformations that are either
heteromeric (alpha2-alpha6 and beta2-beta4), or homomeric (alpha7-alpha9) (Dani,
2001).
Deficits in nicotinic receptors have been implicated in several neurological
disorders including Alzheimer’s disease, Parkinson’s diseases, and Down’s syndrome
(Levin, 2002). Along these lines, agonists targeting the nicotinic receptor system have
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been shown to be neuroprotective. Pre-treatment with nicotine, carbachol (mixed
nicotinic/muscarinic agonist), and nornicotine has been shown to be neuroprotective
against the excitotoxic effects of excessive glutamatergic activity in cortical cell cultures
(Ferchmin et al., 2003; Marin et al., 1994; Akaike et al., 1994). Nicotine treatment can
also reduce cellular toxicity induced by ischemic damage both in-vivo and in-vitro in
gerbils and rats (Pauly et al., 2004). Nicotine can also reduce the damage caused by betaamyloid plaques, related to the development of Alzheimer’s disease (Shimohama et al.,
2001).
In the nicotinic system, evidence for the role of cholinergic systems in the effects
of ethanol exposure stems from research using choline supplementation, an essential
nutrient used in the production of acetylcholine that is also thought to activate nicotinic
receptors. Perinatal choline supplementation been shown to reduce open field
hyperactivity, spatial working memory deficits, eyeblink and trace fear conditioning
deficits (Monk, 2012). Thomas and colleagues (2009) have also found that choline
supplementation in early development can lessen the severity of reduced birth and brain
weight after ethanol exposure (Thomas, 2009). Choline’s effect on cholinergic
functioning in a model of ethanol exposure is thought to be mediated in part by the
nicotinic receptor system, of which choline has been shown to be a direct agonist
(Coutcher, 1992; Thomas, 2013). In animal models, nicotine exposure can reduce deficits
related to learning and memory as well as an ability to increase cell survival after hypoxic
events, brain damage, and excitotoxicity (Hejmadi et al., 2003; Miwa et al., 2011; Levin
& Rezvani, 2000; Lloyd, G. 2000; Pauly et al., 2004; Prendergast et al., 2001a & b).
Research has also shown that nicotine treatment during ethanol administration can reduce
cell death produced by ethanol-related toxicity in cultured granule cells of the cerebellum
(Tizabi et al., 2003). However, nicotine is relatively non-specific for various nicotinic
receptor subtypes causing activation of both central and peripheral cholinergic systems.
This decreases the usefulness of a nicotine-like drug aimed at treating humans. In order to
avoid problems associated with the activation of peripheral targets and find a drug that
specifically and exclusively activated neuronal nicotinic receptors, other compounds need
to be explored.
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Alpha-7 Nicotinic Acetylcholine Receptor
Of the nicotinic receptors implicated in nicotine’s neuroprotective effects, the
alpha 7 nicotinic acetylcholine receptor (α-7 nAChR) is of particular interest because of
its high concentration in neuronal tissue throughout the CNS (Dani, 2001). Stimulation
of the α-7 nAChR has increased cognition and decreased behavioral deficits in animals
(Timmermann et al., 2007; Olincy et al., 2007). This receptor has also been implicated in
mediating synaptic plasticity and regulation of immune function (Kem, W. 2000).
Activation of the receptor can result in a reduction in cellular toxicity from ethanol
withdrawal (de Fiebre et al., 2003 & 2005; Yangxin et al., 2002), neuroinflammation
(Concepcion et al., 2008; de Jonge et al., 2007), glutamatergic toxicity (Dajas-Bailador et
al., 2000 & Shimohama et al., 1998), and traumatic brain injury (Pauly et al., 2004) .
α-7 nicotinic receptors are some of the most heavily expressed nicotinic receptors
in the CNS, and to a lesser extent in the immune system (Dani, 2001). High densities of
this receptor are found in the hippocampus, cerebellum, prefrontal cortex, motor cortex,
and basal ganglia (Dani, 2001; Concepcion et al., 2008). The expression of the α-7
nAChR is first observed on neuroblasts early in gestation (Miwa et al., 2011). Also,
receptor expression steadily increases until birth. In the third trimester, the density of α-7
receptors in the hippocampus is roughly 3x that of an adult (Miwa et al., 2011). The
receptor responds endogenously to several compounds; in adults this is more commonly
ACh, but in the neonate it is postulated that choline is the primary endogenous compound
acting at the receptor (Miwa et al., 2011). Choline, which has a greater presence in
neonates than adults, has roughly 3x the affinity on the α-7 than does ACh (Miwa et al.,
2011). Activation of hippocampal α7 nAChRs has led to decreases in learning and
memory deficits commonly associated with diseases like Alzheimer’s (Meyer et al.,
1998; Timmermann et al., 2007). In neurons, these receptors are located on the cell at the
axon terminal, the pre-terminal (region just before the terminal that can affect several
terminals at once), postsynaptic dendritic membrane, and on glial cells (Albuquerque et
al., 2009). The α7 nAChR is selectively permeable to calcium, and is responsible for fast
postsynaptic transmission, the modulation of release of numerous transmitters, and longterm potentiation in various areas throughout the brain (Hurst et al., 2013; Dani, 2001;
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Fabian-Fine et al., 2001). Its permeability to calcium is unique in that the receptor does
not require depolarization of the neuron to open (Timmermann et al., 2007). Activation of
alpha-7 nAChRs produces a modulatory action which stimulates the release of several
neurotransmitters (Timmermann et al., 2007). The α-7 nAChR plays many roles in
modulating processes in the brain both pre- and postsynaptically. Postsynaptically, α-7
nAChRs are found on inhibitory GABA’ergic interneurons throughout the hippocampus
and receive input from the medial septal nuclei, which plays a role in sensory response
within this structure (Miwa et al., 2011). This modulation of inhibitory GABA’ergic
interneurons causes the decrease of glutamatergic response in the pyramidal cells of the
hippocampus (Miwa et al., 2011). Choline administration during late gestation, during
peak α-7 nAChR density, can decrease the number of these receptors and increase
excitability and dendritic development in the hippocampus (Miwa et al., 2011). However,
choline deficiency, a common occurrence during gestation, is thought to be damaging to
the developing CNS. Choline supplementation has been shown to be neuroprotective in
several paradigms, including animal models of FAS/FASDs (Miwa et al., 2011; Pauly et
al., 2004; Thomas et al., 2004, 2007 & 2009). Also, in late prenatal to early postnatal
development, the α-7 nAChR is responsible for the transformation of glutamate
neurotransmission from primarily NMDA-type to kainate-aspartate receptors (Miwa et
al., 2011). These actions could be important in the α-7 nAChR’s effects in mediating the
excitotoxic response to ethanol withdrawal. Because ethanol withdrawal is commonly
associated with increased activity of glutamatergic receptors that can lead to excitotoxic
death, it seems contradictory that possibly stimulating its release through α-7 agonism
would decrease excitotoxicity. Several mechanisms could be at work to reduce EWDinduced toxicity. One of the most commonly postulated mechanisms of action for the α-7
nicotinic receptors’ effects on ethanol neurotoxicity is the ability of the receptor to reduce
calcium toxicity, caused by activation of the NMDA receptor during ethanol withdrawal
(de Feibre et al., 2003; Shimohama et al., 1998). For review on NMDA-induced toxicity
during ethanol withdrawal (see Tsai et al., 1998; Kalluri et al., 1998; Grant et al., 1990;
Eckardt et al., 2006; or Prendergast et al., 2001a. and b.). Nicotine administration during
ETOH withdrawal (EWD) has been shown to decrease this calcium-induced
excitotoxicity through several possible metabolic mechanisms including the buffering of
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internal calcium stores due to calbindin D28K (a calcium sequestering protein) during
early development (Prendergast et al., 2001 a.). Prendergast and colleagues (2001 a.) also
believe that activation of the α-7 nicotinic receptor could possibly be down-regulating the
expression of the NMDA receptor and decreasing withdrawal-induced toxicity
Administration

of

the

nicotinic

antagonists

alpha-bungarotoxin

(BTX)

or

methyllycaconatine (MLA), which block the α-7 nAChR, negates nicotine’s protective
effects in NMDA-induced toxicity supporting the role of α-7 receptors in neuroprotection
(Ferchmin et al., 2003). Another mechanism postulated to lessen EWD-induced toxicity
is to reduce the release of reactive oxygen species and cytochrome C (a signal for
apoptosis) from the mitochondria (also the primary store for intracellular calcium) caused
by α-7 nAChR activation (Li et al., 2000 & 2002). This process is thought to be
modulated by the activation of protein kinase C (PKC), which can reduce the release of
cytochrome C (Li et al., 2002). Further support for α-7 nAChR’s role in reduction of
toxicity induced by EWD stems from data showing that α-7 nAChR knockout (KO) mice
do not display nicotine-induced neuroprotection (Gahring et al., 2003).
DMXB-A
DMXB-A is a derivative of an anabaseine compound found in marine worms
(Olincy & Stevens, 2007). It has a high affinity for the α-7 nAChR, showing about 40%
of the efficacy of ACh for the receptor and a much lower affinity for other nicotinic
receptors like the α4β2 and type 3 5-HT receptors where it acts as an antagonist (Kem et
al., 2006; de Feibre, 2003; Olincy & Stevens 2007). Studies have shown that DMXB-A
may act as a noncompetitive partial-agonist with higher doses desensitizing the receptor
and lower doses activating them (Kem et al., 2006). It is a lipophilic compound that
readily crosses lipid membranes such as the blood brain barrier (BBB) easily (Kem et al.,
2006). In the human brain, DMXB-A is less potent than nicotine (Ki=2000) when
displacing α-BTX, however in the rat brain DMXB-A is more potent than nicotine at
displacing α-BTX at the α-7 nAChR (Ki=650) (Briggs et al., 1997).
Many studies looking at α-7 nAChR’s protective properties have used 3dimethoxybenzylidene-anabasine (DMXB-A) or otherwise known as GTS-21. The drug
was the first α-7 nAChR agonist to be used in clinical testing for the treatment of
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schizophrenia, Parkinson’s disease, and Alzheimer’s disease (AD) (Freedman et al.,
2014; Kem et al., 2006; Meyer et al., 1997). In phase II clinical studies of patients with
schizophrenia, DMXB-A improved attention and memory and sensory inhibition in an
animal model of schizophrenia (Freedman et al., 2014; Olincy et al., 2007). DMXB-A
was neuroprotective against beta-amyloid toxicity in an animal model of AD (Kem,
2000; Kihara et al., 1997). DMXB-A also improves cognitive function following
administration of beta-amyloid (Chen et al., 2010; Meyer et al., 1997). DMXB-A has also
shown to be neuroprotective in animal models of global ischemia (Nanri et al., 1998).
Data from in-vitro studies also suggest that DMXB-A can dose-dependently reduce cell
death following ETOH exposure (de Fiebre et al., 2003; Li et al., 2000 & 2002;
Shimohama et al., 1997). Using an embryonic primary hippocampal cell culture model to
study the effects of DMXB on ethanol toxicity, De Fiebre and colleagues (2003) found
that DMXB effectively increased cell viability after ethanol administration. Also, pretreatment with DMXB-A at low doses increases cell survival during an ethanol challenge
(Li et al., 1999). Most previous studies either used a pre-treatment or a concomitant
method for administering DMXB-A with ethanol, but no previous research using a thirdtrimester chronic ethanol model with post-ethanol exposure of DMXB-A has been
examined. Thus, further investigation into the therapeutic potential for DMXB-A is
warranted.
The exact mechanism with which activation of the α-7 nAChR works to reduce
the toxic effects of ethanol exposure and withdrawal remain somewhat unclear. However,
as mentioned above, this process is most likely mediated by several different mechanisms
that work in unison to reduce toxicity. Studies that have explored the interaction between
DMXB-A and ethanol-induced toxicity have shown that the drug prevents ethanolinduced increases in intracellular calcium, the buildup of reactive oxygen species, and the
release of cytochrome C (Li et al., 2000). Other studies have suggested that the protective
effects of DMXB-A might not be due solely to the activation of the α-7 receptor, but due
to action on other nicotinic receptor subtypes as well (de Feibre et al., 2003). Another
emerging hypothesis using a neuro-inflammation model, indicates the actions of α-7s
expressed on microglia and possibly macrophages could contribute to the neuroprotection
in models of cellular stress (Parada et al., 2013). However, no research, to the best of my
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knowledge, has examined the effects of DMXB-A on “third trimester” ETOH exposure
using either an in vivo or in vitro rodent model.
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Chapter 2:
Testing DMXB-A’s Effects in an Organotypic Hippocampal Slice Culture Model
Hypothesis
The current hypothesis is that the α-7 nAChR agonist DMXB- A should reduce
the amount of cell damage caused by chronic ethanol exposure and withdrawal in a
developmental organotypic hippocampal slice culture in a rodent model. Investigation
into this is of importance in furthering the understanding of the potential therapeutic
efficacy of α-7 agonists on the development of FAS/FASDs.
Methods:
Organotypic Hippocampal Slice Culture: Overview
The organotypic hippocampal slice culture (OHSC) model was developed in 1981
by Gahwiler and colleagues (Gahwiler, 1981) and simplified by Stoppini and colleagues
in 1991 (Stoppini et al., 1991). OHSC has since been used as an investigative tool to
study both pharmacological and environmental manipulations that could provide
neuroprotection, neurogenesis, and/or neurotoxicity.

The OHSC model has many

benefits relative to simpler in-vitro culture models (like primary cell culture models) that
make it a useful model to use when investigating neurotoxicity. First, it allows for the
maintenance of neurons and glia and maintains much of the complex circuitry of an intact
hippocampus (Noraberg et al., 2005), providing a more valid model in assessing
neuroprotection and neurorepair and allowing easy quantification of cell markers,
including cell damage. This model also allows investigators to characterize compounds of
interest, possibly revealing their mechanism of action. Through much investigation
OHSC has shown sensitivity to a variety of insults including ETOH; for review see
(Noraberg et al., 2005).
Hippocampal slice culture models are particularly useful for studying excitotoxic
damage related to chronic ethanol exposure in the current study because of the
susceptibility of the hippocampus to toxicity related to ethanol withdrawal. As stated
previously, the hippocampus is also useful in a culture model using DMXB-A because of
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the high concentration of α-7 nAChRs which have been implicated in EWD-related
neuroprotection in this structure. Also, the hippocampus is heavily implicated in some of
the cognitive and behavioral deficits observed following fetal alcohol exposure, such as
impaired learning and memory.
Animals
Male and female Sprague-Dawley rat pups were used for this experiment. The
animals were obtained through breeding in the rat vivarium in Kastle Hall. All animals
were housed in a 12 hour light/dark cycle, and were allowed continuous access to food
and water. After each breeding session pregnant females were identified by the presence
of a vaginal plug. Pregnant females were removed from the colony and taken to a
temperature and humidity controlled nursery for the duration of their pregnancy. After
parturition, pups remained with their mother until postnatal day (PND) 1. On PND 1,
litters were culled to 10, maintaining 5 male and 5 female pups when possible; allowing
for an even distribution of subjects between the experimental groups and sexes. The care
of animals was carried out in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996), as
well as the University of Kentucky’s Institutional Animal Care and Use Committee
Hippocampal Slice Culture Preparation and Treatments
On PND8, non-treated litters were sacrificed for brain removal. The brains were
removed and placed in a tissue culture dish containing dissecting medium [Minimum
Essential Medium (Gibco BRL, Gaithersburg, MD), 25 mM HEPES (ATCC, Manassas,
VA), 200 mM L-glutamine (Invitrogen, Carlsbad, CA), 50 μM streptomycin/penicillin
(ATCC, Manassas, VA)]. The hippocampus from each brain was removed and then
sliced coronally at 200 um using a McIllwain Tissue Chopper (Campden Instruments
Ltd., Lafayette, ID). Slices were separated and placed on Teflon membrane inserts
(Millicell-CM 0.4 μm; Millipore, Marlborough, MA, USA). Each insert holds 3 slices
with 6 inserts per culture plate. The wells contained 1mL culture media [dissecting
media, 36 mM glucose, 25% Hanks’ balanced salt solution (HBSS; Gibco BRL,
Gaithersburg, MD), 25% heat-inactivated horse serum (HIHS; Sigma, St. Louis, MO)].

20

Plates were then placed in an incubator (37°C/5%CO2/95%air) for 5 days in vitro (DIV)
for adherence to the Teflon membrane.
On DIV 5, the inserts were split into a 100mM ETOH-treated and control groups.
After the groups were divided, the 6 well plates were placed into propylene containers
with 50mL of control or 100 mM ETOH (averaging approx. 65mM over 5 days in vitro
[Prendergast et al. 2004]) in sterile water with 50uM gentamicin added to avoid chances
of bacterial growth. The plates were placed into plastic freezer bags and inflated with an
air mixture to prevent ETOH evaporation. This procedure was repeated on DIV 10 to
provide the slices with fresh ETOH. On DIV 15 the slices were removed from control or
ETOH media and treated with a combination of DMXB-A (at 0, 1, 3 or 10uM) control
media, and/or NMDA (5um), giving a total of 16 treatment groups (Table 1.). During the
24-hour treatment period, slices were also exposed to the fluorescent marker propidium
iodide (PI; 3.74 μM, SigmaAldrich). PI is an indicator of cellular damage because it binds
to the DNA of cells whose membranes have been compromised (in this case by EWDinduced toxicity) and produces red fluoresces when exposed to 488nm waves of light.
Twenty-two hours later, slices were imaged using fluorescent microscopy. The images
were captured using SPOT Advanced version 4.0.9 software for Windows (W.
Nuhsbaum Inc., McHenry, IL, USA) using a 5X objective connected to an inverted Leica
DMIRB microscope (W. Nuhsbaum Inc.) fitted for fluorescence detection (mercury-arc
lamp) and connected to a computer via a SPOT 7.2 color mosaic camera (W. Nuhsbaum
Inc.). PI uptake in the CA1, CA3, and DG cell layers were measured using ImageJ
version 1.46 software (National Institute of Health).

Raw fluorescent values were

obtained by subtracting the background signal from the cell layer fluorescence.
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DIV 0-5

Control

DIV 5-15

100mM ETOH

Control

DIV 15

0 DMXB (+/- 5µM
NMDA)

1µM DMXB (+/5µM NMDA)

3µM DMXB (+/5µM NMDA)

10µM DMXB (+/5µM NMDA)

Table 1.
Treatment Groups: 2 control groups, 2 NMDA groups, 6 DMXB groups, 6
NMDA+DMXB groups.
Power Analysis
Before beginning the study, an apriori analysis was run to determine the number
of culture preparations needed to achieve 90% power when detecting a medium-sized
effect (f= .25) in a study using 16 groups. This required a minimum of 6 culture
preparations at roughly 144 slices per prep.
Statistical Analysis
Analyses were conducted using IBM Statistical Package for the Social Sciences
(SPSS) version 22 software (IBM Corporation, 2014). First, the three regions of the
hippocampus were analyzed together to determine if there were differences in treatment
groups between the regions. After this, each hippocampal region was investigated using a
2-way (sex x group) univariate general linear model (GLM) analysis of variance
(ANOVA) to explore variance in and among the factors. Each culture replication was
also used as a covariate during initial analysis to assess the effect of litter on the
individual repetitions of each culture preparation.

If significant interactions were

detected, further investigation using a post hoc pair-wise comparison with Tukey’s
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correction for family-wise error was used. For simple graphical representation, mean
levels of toxicity for each group were converted to percent control.
Results
To investigate whether there were group differences between the three regions of
the hippocampus (CA1, DG, and CA3), an ANOVA was run with region as a repeated
measure. The ANOVA was a 2 (sex) x 3 (region) x 16 (treatment) design.
Analysis revealed that there was that there was a main effect of treatment between
the three regions, where F(1, 15)=11.805 ,p<.001, and sex F(1,15)=9.753, p<.005, with a
non-significant interaction between the two of F(1,15)=1.420, p=.130. Because of
previous research in this lab and others using an OHSC model of EWD supporting
variations in outcome between the three regions (specifically the CA1), an a-priori
hypothesis warranted the investigation of the individual regions separately.
CA1
In the CA1, using a 2-way ANOVA (treatment x sex), there was a main effect of
treatment F(15,31)=10.851, p<.001 and an interaction between treatment and sex
F(15,31)=1.811, p<.05. Because of this interaction between treatment and sex in the
CA1, further analyses in this region were completed separately by sex. For both males
and females there was a main effect of treatment F(15,15)=6.752, p<.001, and
F(15,15)=5.954, p<.001 respectively. Because of this, a Tukey’s correction for familywise error post hoc test was utilized to explore these group differences. Significance was
set at p<.05.
In slices exposed to ETOH + NMDA that were treated with 1, 3, and 10um of
DMXB-A, there was a significant reduction in fluorescence (p<.005 for females at all
three doses, and p<.05 for males at all three doses) compared to ETOH + NMDA alone
(fig.1). Female slices treated with ETOH+NMDA alone showed greater fluorescence
when compared to controls than did male slices (197% vs 163% fluorescence of control,
respectively) (fig.1).
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Differences between males and females also persisted with exposure to NMDA.
Male slices exposed to NMDA alone expressed greater fluorescence compared to control
slices (188% of control, p<.001) than did female slices (141% of control, p<.05) (fig.2).
In males, increasing the dose of DMXB-A reduced PI fluorescence, and at 3 and 10 μm
DMXB-A, this difference was significant (p<.05 for both doses) (fig.2). However, in
females, when treated with 1μm DMXB-A, fluorescence significantly increased
compared to NMDA alone (p<.005) (fig.2). This increase in fluorescence was reduced to
near control levels in females treated with 10 μm DMXB-A.
When treated with ETOH (fig. 3), slices were not significantly different between
males and females. Fluorescence in slices treated with ETOH alone was comparable to
control slices. However, when treated with 3 and 10 μm DMXB-A, both male and
females slices had increased fluorescence compared to controls; this difference was
significant for males at 3μm DMXB-A (p<.05) and for females at 10μm DMXB-A
(p<.05).
In control slices, for both sexes, treatment with 1μm DMXB-A produced levels of
fluorescence comparable to controls (fig.3). However, treatment with 3μm of DMXB-A
produced a significant increase in PI fluorescence compared to controls (females
[p<.005], males [p<.05])(fig.3).

However, only in males did treatment with 10μm

DMXB-A produce significantly increased fluorescence when compared to controls
(p<.001) (fig.4).
CA3 & DG:
In both regions there was a main effect of treatment, F(15,31)=14.767, p<.001 for
the CA3 and F(15,31)=15.330, p<.001 for the DG. Unlike the CA1, there was no effect of
sex and no interaction between treatment and sex.

To investigate individual group

differences a Tukey’s correction for family-wise error post-hoc test was utilized, and
significance was set at p<.05.
In the CA1, fluorescence in control slices for both the DG and CA3 when treated
with 1, 3, and 10 μm DMXB-A was significantly increased when compared to controls
(p<.05 or greater for all three doses in both regions) (fig.5). This increase in fluorescence
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was closer to control levels only in slices treated with 1μm DMXB-A (around 117%
fluorescence of control) (fig. 5).
In slices exposed to ETOH, treatment with 3 and 10 μm DMXB-A significantly
increased fluorescence when compared to controls in both regions (p<.05) (fig. 6). This
increase was not present in ETOH slices treated with 1μm DMXB-A for either region. In
Slices exposed to NMDA, for both regions, there was a significant increase in
fluorescence compared to controls (p<.05) (fig. 7). This also occurred in NMDA exposed
slices when treated with 1 and 10μm DMXB-A. However, this increase in fluorescence
was not found in NMDA slices treated with 3μm DMXB-A (fig. 7). Finally, in slices
exposed to both ETOH and NMDA, for both regions, there was no difference in
fluorescence when compared to controls (fig. 8). These results persisted with all three
doses of DMXB-A in both regions.

25

Figures:

250

CA1: ETOH +NMDA
Female
Male

Cell damage as % control

*
200

*

150

100

0

0µm-DMXB-A

1µm-DMXB-A

3µm-DMXB-A

10µm-DMXB-A

* p<.05, differs significantly from control

Fig 1. PI uptake expressed as percent control in the CA1 region of the hippocampus, in
slices exposed to ETOH+NMDA 24 hours after ethanol withdrawal, treated with four
levels of DMXB-A (0, 1, 3, and 10 μm). ETOH/NMDA slices treated with 1, 3, and 10
μm DMXB-A had significantly reduced PI expression compared to ETOH/NMDA slices.
*p≤.05, differs significantly from control slices.
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Fig 2. PI uptake expressed as percent control in the CA1, in slices exposed to NMDA,
treated with four levels of DMXB-A (0, 1, 3, and 10 μm). Male slices exposed to NMDA
alone expressed greater fluorescence compared to control than did female slices (188% vs
141% of control, respectively), but when treated with 1μm DMXB-A, fluorescence in
females slices exposed to NMDA was greater than males (203% vs. 158% of control,
respectively). *p≤.05, differs significantly from control slices.
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Fig. 3: PI uptake expressed as percent control in the CA1, in slices exposed to ETOH,
then treated with four levels of DMXB-A (0, 1, 3, and 10 μm). ETOH exposure alone did
not increase fluorescence compared to controls. 3 and 10 μm DMXB-A increased
fluorescence in slices treated with ETOH in both sexes. When treated with 1 μm DMXBA, fluorescence was comparable to control slices. *p≤.05, differs significantly from
control slices.
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Fig 4. PI uptake expressed as percent control in the CA1, in control slices, treated with
four levels of DMXB-A (0, 1, 3, and 10 μm). DMXB-A increased fluorescence with all
three levels of DMXB-A in both sexes. Slices treated with 1μm DMXB-A, however, did
not differ significantly from control slices. *p≤.05, differs significantly from control
slices.
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Fig. 5: PI uptake expressed as percent control in the Dentate Gyrus and CA3 in control
slices treated with four levels of DMXB-A (0, 1, 3, and 10 μm). For both regions,
treatment with DMXB-A significantly increase fluorescence compared to control slices.
However, 1μm DMXB-A reduced this fluorescence compared to both 3 and 10 μm
DMXB-A. *p≤.05, differs significantly from control slices.
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Fig. 6: PI uptake expressed as percent control in the Dentate Gyrus and CA3 in ETOH
slices during EWD, treated with four levels of DMXB-A (0, 1, 3, and 10 μm). For both
regions, treatment with 3 and 10 μm DMXB-A significantly increase fluorescence
compared to control slices. However, 1μm reduced this fluorescence compared both 3
and 10 μm DMXB-A. *p≤.05, differs significantly from control slices.
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Fig. 7: PI uptake expressed as percent control in the Dentate Gyrus and CA3 in NMDA
exposed slices, treated with four levels of DMXB-A (0, 1, 3, and 10 μm). NMDA alone
significantly increased fluorescence for both regions when compared to controls.
Treatment with 1 and 10μm DMXB-A also significantly increased fluorescence for both
regions when compared to controls. Treatment with 3μm DMXB-A in NMDA exposed
slices did not significantly differ from controls. *p≤.05, differs significantly from control
slices.
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Fig. 8: PI uptake expressed as percent control in the Dentate Gyrus and CA3 in
ETOH+NMDA exposed slices during EWD, treated with four levels of DMXB-A (0, 1,
3, and 10 μm). Exposure to ETOH+NMDA alone and ETOH+NMDA slices treated with
3 and 10μm DMXB-A did not significantly differ from control slices. When treated with
1μm DMXB-A, NMDA exposed slices decreased in fluorescence compared to controls.
*p≤.05, differs significantly from control slices.
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Discussion
DMXB-A’s Role in Reducing Toxicity during EWD
In this study, toxicity in PND8 hippocampal slices undergoing various challenges
were examined. These challenges included EWD after 10 day chronic binge-like
exposure to 100mM ETOH in the presence or absence of an NMDA challenge, NMDA
challenge alone, and the effect of various doses of DMXB-A on these groups and in
healthy untreated slices. In support of the hypothesis, and in agreement with previous
work using DMXB-A, our results suggest that DMXB-A may be neuroprotective against
excitotoxicity associated with EWD during an NMDA challenge. This effect was seen in
both males and females at all three concentrations of DMXB-A. The fact that DMXB-A
reduced this toxicity was not surprising because of previous research supporting the role
of the nicotinic system (and in many cases the α-7 nAChR) in protecting against various
forms of cellular damage including GLU/NMDA toxicity, EWD related toxicity, βamyloid toxicity, and hypoxia (Akaike et al., 1994; Dajas-Bailador et al., 2000; Kihara et
al., 1997; Hejmadi et al., 2003; Marin et al., 1994; Prendergast et al., 2001 A & B).
Previous studies using DMXB-A have also found similar results; where toxicity induced
by GLU/NMDA or ETOH/EWD is reduced by treatment with DMXB-A (de Fiebre et al.,
2003; Li. et al., 1999 A & B, 2000 & 2002; Shimohama et al., 1997).
After investigating the effect of EWD without NMDA challange, it was found
that EWD alone did not produce significant amounts of toxicity. This finding was not
surprising and has been supported previously, where 24 hour EWD alone produced
significantly less toxicity than slices treated with ETOH given an NMDA challenge
(Wilkins et al., 2006). However, the level of ETOH used in this study was actually quite
high, averaging about 65mM (roughly equivalent to 299 mg/dl) ETOH over the 10 day
exposure period (Prendergast et al., 2004). This minimal toxicity is thought to occur
because of insufficient glutamate levels in cultured hippocampi during EWD (Wilkins et
al., 2006). In-vivo glutamate levels actually increase during EWD (Dahchour & De
Witte, 1999) so, NMDA was used to induce toxicity during EWD in this model because,
as described above, most of the toxicity caused by EWD is thought to be mediated by
overexcitation of the NMDA type glutamatergic receptor (for review see Tsai et al.,
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1998; Kalluri et al., 1998; Grant et al., 1990; Eckardt et al., 2006; or Prendergast et al.,
[2001a and b]). NMDA induced toxicity in the absence of ETOH was also observed in
the current study. Many previous studies (discussed above) use glutamatergic/NMDA
insult to produce excitotoxicity without the presence of ETOH/EWD in various models of
cellular culture, including OHSC (Akaike et al., 1994; Dajas-Bailador et al., 2000;
Prendergast et al., 2001 A & B; Lewis et al., 2012). Yet, in the presence of ETOH, this
toxicity caused by the addition of NMDA during EWD is thought to be multiplicative
(greater than that of ETOH, or NMDA alone) (Wilkins et al., 2006), and is demonstrated
in other studies from this lab (Lewis et al., 2012). However, this effect was only observed
in females in our study, where NMDA alone produced a modest increase in toxicity and
the addition of NMDA during EWD was significantly more toxic than NMDA alone.
Surprisingly, in males, this did not occur and NMDA alone appeared to be more toxic
than the addition of NMDA during EWD.
Of the previous studies in this lab using male and female slices in an OHSC
model (Barron et al., 2008 and Lewis et al., 2012) looking into NMDA or EWD related
toxicity, there were not any reported significant differences between sexes to these insults
alone. Yet, modulators of the NMDA receptor (i.e. spermidine) that enhance NMDAR
function, have been shown to produce a greater amount of toxicity in females than males
in the CA3 region of the hippocampus (Barron et al., 2008). This toxicity was negated by
an NMDA antagonist ifenprodil, to significantly below control levels in females. This
data was supported by Prendergast and colleagues (2000) who showed similar results in
the CA3 region of the hippocampus. Other work using adenosine antagonists during
ethanol withdrawal have found that granule cells of the dentate gyrus, and pyramidal cells
in the CA3 and CA1 in females showed increased toxicity compared to males (Butler et
al., 2008 & 2009). This toxicity from adenosine receptor antagonism was postulated to
occur via a NMDAR mediated over activation because co-administration of MK-801
(NMDAR antagonist) reduced this toxicity. These studies indicate that there may be
differences between males and females in regard to NMDA and EWD mediated toxicity,
but the differences found in these previous studies do not parallel those found in the
current study. These results and previous findings support a role of sex in the outcome of
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ETOH/EWD and or NMDA toxicity, though it is obvious further work needs to be
conducted to further elucidate these differences.
After treating the slices with various levels of DMXB-A, it was found that the
drug could be potentially toxic at higher doses, and in the presence of ETOH alone, could
be protective against normal culture toxicity. First, the increased PI uptake in both sexes
for the CA1, DG, and CA3 in control hippocampal slices when treated with all three
concentrations of DMXB-A (1, 3, and 10μm) suggest that DMXB-A may be potentially
toxic with the concentrations used in this study. At the lowest concentration of DMXB-A
(1μm), the toxicity was reduced to near control levels in the CA1 without reducing the
neuroprotective qualities of the drug in slices exposed to both ETOH and NMDA. These
results were unexpected because toxicological reports in human clinical trials using
DMXB-A have found that the drug is well-tolerated and safe (for review see Kem et al.,
2006). However, Li and colleagues (1999) found that acute administration with high
levels (30μm) of DMXB-A could cause toxicity. This characteristic could be a result of
the drug’s potential partial-agonist actions on the α-7 nAChR’s (reviewed in Kem, 2006).
In fact, in Li’s (1999) study, they hypothesized that this toxicity is produced by a rapid
desensitization of α-7 nAChR’s in response to high levels of DMXB-A, and that lower
doses would pro-long receptor activation and cause neuroprotection. However, Treinin
and colleagues (1995) found that in a non-desensitizing mutated form of the α-7 receptor
there was reduced cellular viability in response to calcium overload. And other studies
have shown that using small amounts of selective α-7 antagonists (MLA) can produce
some minor neuroprotection (Li. 1999). So there seems to be an ideal amount of receptor
activation that promotes neuroprotection and not neurotoxicity. This interaction is unique
because this same pattern of toxicity is seen in ETOH slices. Again, ETOH alone did not
produce any significant amounts of toxicity, but when ETOH slices were treated with
higher levels of DMXB-A (3 or 10 μm) significant levels of toxicity was observed in all
three regions of the hippocampus treated with ETOH. Also, like in control slices, the
lowest dose (1μm) of DMXB-A in ETOH slices reduced toxicity to below control levels,
and actually produced a significant reduction of toxicity below control slices in the CA3
and DG. Though toxicity levels in control slices treated with 1μm DMXB-A were not
significantly different from un-treated “healthy” slices, they still displayed significantly
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more toxicity than ETOH slices treated with 1μm DMXB-A. This could possibly mean
that modulation of the α-7 nAChR in a state of challenge (i.e. EWD) is crucial for its
protective abilities, and that activation of this receptor in healthy cells is potentially toxic.
Even more interesting though, is that DMXB-A when administered with the combination
of ETOH and an NMDA challenge, reduced toxicity to near control levels at all three
doses (1, 3, and 10μm); and that treatment with DMXB-A after NMDA challenge alone
did not reduce toxicity to control levels at any concentration of the drug. These were a
series of surprising findings that had not been previously observed. Because DMXB-A
was only neuroprotective against EWD + NMDA induced toxicity, but not NMDA alone,
and the fact that both forms of toxicity are thought to work in the same way (e.g. calcium
toxicity), it appears that there is a crucial mechanism that exists between the α-7 nAChR,
EWD, and NMDA that does not occur otherwise. It may support the idea that DMXB-A
is acting as a partial-agonist at the α-7 nAChR, but this relationship seems to be much
more complex involving several mechanisms that may or may not directly involve the
NMDA receptor in protection against EWD induced toxicity.

However, this process

remains unclear and further research is needed to determine the NMDA receptors role in
this process.
Limitations and Future Directions
In this study we showed that DMXB-A protects against EWD induced toxicity
during an NMDA challenge in the hippocampi of PND 8 male and female rats. Future
studies could address some potential limitations of this study. It is possible that the
underlying mechanism of action of DMXB-A is not solely due to its action on α-7
nAChR activity since DMXB-A could have effect on other ionotropic transmembrane
receptors (as discussed above). This question could be addressed by using more highly
selective α-7 nAChR antagonists (like MLA & α-BTX) in the presence of DMXB-A.
Previous studies (as described above) using this method have found that DMXB-A’s
neuroprotective effects were negated by the use of selective α-7 nAChR antagonists such
as (MLA and α-BTX) (refer to De-Fiebre et al., 2003; Li. et al., 1999, 2000 & 2002;
Shimohama et al., 1997), the use of these drugs in our model would provide further
evidence of the α-7 nAChR’s involvement in reducing toxicity induced by EWD.
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However, it is also unclear if direct activation of the α-7 nAChR mediates the actions of
other neurotransmitter systems to prevent cellular toxicity. It is thought that EWD and
NMDA produce toxicity in a similar manner (Wilkins et al., 2006), but the current
findings showed that DMXB-A was only able to reduce toxicity when NMDA and EWD
was combined, but not from NMDA challenge alone. It is crucial to investigate the role
of the NMDA receptor in this model using DMXB-A. One possible route could be to
selectively antagonize the NMDA receptor to see if DMXB-A’s toxic and protective
actions persist after NMDA has been taken out of the equation. Other neurotransmitters
systems found in the hippocampus have been implicated in the α-7 nAChR’s protective
actions.

It has been hypothesized that a reduction in symptoms associated with

schizophrenia and the toxicity of β-amyloid is associated with the mediation of GABA-A
receptors on hippocampal interneurons by the α-7 nAChR (Benes, 2012; Miwa et al.,
2011). Evidence for this modulation comes from research showing that activation of the
α-7 nAChR increases GABA-A transmission in cultured hippocampal cells (Arnaiz et al.,
2008) and that activation of these receptors can be protective against various forms of
cell death and toxicity (Paula-Lima et al., 2005; Rosato-Siri et al., 2006; Miwa et al.,
2011). Modulation of these GABA’ergic interneurons in our model could possibly be
mediating the protective effect of DMXB-A against EWD toxicity during NMDA
challenge. This hypothesis could be tested by co-administration of DMXB-A and
selective GABA-A antagonists during EWD during an NMDA challenge. If DMXB-A’s
protective effects are indeed mediated through activation of GABA’ergic interneurons,
then a GABA-A antagonist would negate DMXB-A’s protective effects. Other
possibilities to investigate the outcomes of DMXB-A treatment is the use of
immunohistochemical techniques using compounds like NeuN to investigate neuronal
tissue survival. NeuN is a nuclear antigen that stains specifically for mature neurons, and
could be used in combination with propidium iodide which stains any cell type that has a
compromised membrane (Mullen et al., 1992; Riccardi & Nicoletti 2006). This could
help inform us to whether DMXB-A is selectively rescuing neurons and if
neuroprotection may also occur for other cell types during EWD (astrocytes, microglia,
etc.).
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Previous work with both nicotinic agonists, and DMXB-A in both humans and
animals have found that these drugs can be protective against behavioral deficits
associated with various diseases and forms of toxicity (for review see Kem et al., 2000;
Olincy & Stevens 2007). Because of this, future in-vivo work with DMXB-A must be
conducted. This work is important for testing the possible therapeutic effects of this drug
in our third trimester model of ethanol exposure in rodents because of its current use in
clinical trials to treat diseases like schizophrenia and Alzheimer’s disease (3 clinical trials
in recruiting phase as of 2015; info gathered from clinicaltrials.gov). This increases
DMXB-A’s translation potential, and makes it a promising candidate for further work in
models of fetal ethanol exposure. Completing behavioral work with DMXB-A is
necessary to further explore the possibly neuroprotective nature of DMXB-A. Studies
using this drug and other nicotinic compounds are critical to increase the understanding
the role the nicotinic system plays in protecting against ethanol related deficits and
toxicity.
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